Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Kalra, S; Lowndes, C; Durant, L; Strange, RC; Al-Araji, A; Hawkins, Clive P; Curnow, S John
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 6:Issue 1(2020)
• Publication Date: 2020-01
• Subjects: multiple sclerosis -- Th17 -- Th17.1 -- Th22 -- Th1 -- CCR6; Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/2055217319899695
• Languages: English
• ISSNs: 2055-2173

Abstract

Background: The nature and extent of inflammation seen in multiple sclerosis (MS) varies throughout the course of the disease. Changes seen in CD4+ T-helper cells in relapsing–remitting (RR) MS and secondary progressive (SP) MS might differ qualitatively and/or quantitatively. Objective: The objective of this paper is to study the frequencies of all major CD4+ T-helper subtypes – Th17, Th22 and Th1 lineage cells – in relapse, remission and secondary progression alongside CCR6 status, a chemokine receptor involved in migration of these cells into the central nervous system. Methods: We compared 100 patients (50 RRMS and 50 SPMS) and 50 healthy volunteers and performed flow cytometric analysis of lymphocytes in blood samples. Results: We demonstrated raised frequencies of various cell types along the Th17 axis; Th17, Th17.1 (IL-17+ interferon gamma+) and dual IL-17+ IL-22+ cells in RRMS. Th22 and CCR6+ Th1 cells (nonclassical Th1) were also increased in RRMS. All these cells were CCR6+. Only Th17 frequencies were elevated in SPMS. Conclusions: Increased frequencies of Th17 cells are implicated both in RRMS and SPMS. The CCR6 pathway includes Th17, Th22 and Th1 nonclassical cells, of which Th22 and Th1 cells represent the greatest subsets in MS.